Literature DB >> 36094773

Aseptic meningitis in Fabry disease due to a novel GLA variant: an expanded phenotype?

Paulo Ribeiro Nóbrega1,2, João Lucas Araújo Morais3, Alliane Milliane Ferreira4,5, Alisson Dantas de Medeiros3,4, Beatrice Araújo Duarte3, Deborah Moreira Rangel1,4, Fabrício Oliveira Lima4, Anderson Rodrigues Brandão de Paiva2, Luciana Paim-Marques5, Fernando Kok2,6, André Luiz Santos Pessoa7, Pedro Braga-Neto8,9, Fernanda Martins Maia Carvalho4,5.   

Abstract

BACKGROUND: F abry disease (FD) is an X-linked lysosomal storage disorder with accumulation of globotriosylceramide, causing neurologic involvement mainly as acroparesthesias and cerebrovascular disease. Aseptic meningitis has been reported in 11 patients with FD, but no prior study has correlated alpha-galactosidase (GLA) specific variants with meningitis. We present in this manuscript a family in which a novel GLA pathogenic variant was associated with aseptic meningitis in 2 of 5 family members.
METHODS: This study began with identifying the proband, then screening family members for FD symptoms and evaluating symptomatic individuals for genetic and biochemical status. All patients underwent magnetic resonance imaging, and those with headache underwent cerebrospinal fluid (CSF) analysis.
RESULTS: Five patients (3 females) from a single family were included in this study. Mean age at diagnosis was 20.6 years. Two patients (40%) had aseptic meningitis; one of them also had cerebrovascular events. C-reactive protein and erythrocyte sedimentation rate were elevated during aseptic meningitis episodes. Both patients responded to intravenous methylprednisolone with resolution of fever, headache, and vomiting. One of them recurred and needed chronic immunosuppression with azathioprine.
CONCLUSION: We described aseptic meningitis in a family with a novel GLA variant. Meningitis might be a common phenomenon in FD and not a particularity of this variant. Understanding the mechanisms underlying meningitis and its association with cerebrovascular events may lead to a new paradigm of treatment for stroke in these patients. Further prospective studies with CSF collection in patients with FD and recurrent headache could help to elucidate this question.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Enzyme replacement therapy; Fabry disease; Inflammation; Meningitis; Stroke

Year:  2022        PMID: 36094773     DOI: 10.1007/s10072-022-06388-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  38 in total

1.  Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease.

Authors:  T Yoshitama; S Nakao; T Takenaka; H Teraguchi; T Sasaki; C Kodama; A Tanaka; A Kisanuki; C Tei
Journal:  Am J Cardiol       Date:  2001-01-01       Impact factor: 2.778

2.  Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert J Desnick; Wuh-Liang Hwu
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

3.  High incidence of later-onset fabry disease revealed by newborn screening.

Authors:  Marco Spada; Severo Pagliardini; Makiko Yasuda; Turgut Tukel; Geetha Thiagarajan; Hitoshi Sakuraba; Alberto Ponzone; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

4.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

Review 5.  Fabry disease revisited: Management and treatment recommendations for adult patients.

Authors:  Alberto Ortiz; Dominique P Germain; Robert J Desnick; Juan Politei; Michael Mauer; Alessandro Burlina; Christine Eng; Robert J Hopkin; Dawn Laney; Aleš Linhart; Stephen Waldek; Eric Wallace; Frank Weidemann; William R Wilcox
Journal:  Mol Genet Metab       Date:  2018-02-28       Impact factor: 4.797

6.  Manifestations of Fabry disease in placental tissue.

Authors:  A C Vedder; A Strijland; M A vd Bergh Weerman; S Florquin; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

Review 7.  Anderson-Fabry disease in children.

Authors:  Simona Sestito; Ferdinando Ceravolo; Daniela Concolino
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

Authors:  William R Wilcox; João Paulo Oliveira; Robert J Hopkin; Alberto Ortiz; Maryam Banikazemi; Ulla Feldt-Rasmussen; Katherine Sims; Stephen Waldek; Gregory M Pastores; Philip Lee; Christine M Eng; Laszlo Marodi; Kevin E Stanford; Frank Breunig; Christoph Wanner; David G Warnock; Roberta M Lemay; Dominique P Germain
Journal:  Mol Genet Metab       Date:  2007-11-26       Impact factor: 4.797

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.

Authors:  Hsiang-Yu Lin; Kah-Wai Chong; Ju-Hui Hsu; Hsiao-Chi Yu; Chun-Che Shih; Cheng-Hung Huang; Shing-Jong Lin; Chen-Huan Chen; Chuan-Chi Chiang; Huey-Jane Ho; Pi-Chang Lee; Chuan-Hong Kao; Kang-Hsiang Cheng; Chuen Hsueh; Dau-Ming Niu
Journal:  Circ Cardiovasc Genet       Date:  2009-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.